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Abstract: The 3D printing techniques have been explored extensively in recent years for pharmaceu-
tical manufacturing and drug delivery applications. The current investigation aims to explore 3D
printing for the design and development of a nanomedicine-based oral solid dosage form of a poorly
water-soluble drug. A self-nanoemulsifying tablet formulation of dapagliflozin propanediol monohy-
drate was developed utilizing the semisolid pressure-assisted microsyringe (PAM) extrusion-based
3D printing technique. The developed formulation system consists of two major components (liquid
and solid phase), which include oils (caproyl 90, octanoic acid) and co-surfactant (PEG 400) as liquid
phase while surfactant (poloxamer 188) and solid matrix (PEG 6000) as solid-phase excipients that
ultimately self-nanoemulsify as a drug encapsulated nanoemulsion system on contact with aqueous
phase/gastrointestinal fluid. The droplet size distribution of the generated nanoemulsion from a
self-nanoemulsifying 3D printed tablet was observed to be 104.7 ± 3.36 nm with polydispersity index
0.063 ± 0.024. The FT-IR analysis of the printed tablet revealed that no drug-excipients interactions
were observed. The DSC and X-RD analysis of the printed tablet revealed that the loaded drug
is molecularly dispersed in the crystal lattice of the tablet solid matrix and remains solubilized in
the liquid phase of the printed tablet. SEM image of the drug-loaded self-nanoemulsifying tablets
revealed that dapagliflozin propanediol monohydrate was completely encapsulated in the solid
matrix of the printed tablet, which was further confirmed by SEM-EDS analysis. The in vitro dissolu-
tion profile of dapagliflozin-loaded self-nanoemulsifying tablet revealed an immediate-release drug
profile for all three sizes (8 mm, 10 mm, and 12 mm) tablets, exhibiting >75.0% drug release within
20 min. Thus, this study has emphasized the capability of the PAM-based 3D printing technique to
print a self-nanoemulsifying tablet dosage form with an immediate-release drug profile for poorly
water-soluble drug.
Keywords: dapagliflozin propanediol monohydrate; semisolid extrusion-based 3D printing; self-
nanoemulsifying tablet; nanoemulsion; SEM-EDS analysis; drug dissolution
1. Introduction
In the field of pharmaceutical product development, growing interest is seen in
improving the solubility and dissolution profile of newly discovered drug molecules having
poor aqueous solubility. The concept of developing a lipid-based formulation system
for poorly water-soluble drugs has gained considerable attention as it facilitates drug
solubilization and promotes the gastrointestinal absorption of encapsulated drugs [1,2].
Among various lipid-based formulation approaches, which include the formula-
tion of liposomes [3], microemulsions [4], and nanostructured lipid carriers [5], self-
nanoemulsifying drug delivery systems (SNEDDS) have proven to be the most promising
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approach that consists of drug molecularly dispersed in the isotropic mixture of oil, sur-
factant, and co-surfactant [6]. It forms a stable nanoemulsion system in contact with the
aqueous phase upon oral administration. The SNEDDS upon dispersion endures self-
emulsification in gastric media and encapsulates the poorly soluble therapeutics inside
nano oil droplets and thereby improves the dissolution and absorption rate of the encapsu-
lated drug (schematic illustration in Supplementary Figure S1) [7]. So far, the successfully
developed and marketed SNEDDS formulations for poorly water-soluble drugs include
cyclosporin A (Neoral®), Saquinavir (Fortovase®), ritonavir (Norvir®), etc. However, most
of the currently available marketed products of SNEDDS were developed as liquid formu-
lations, which were filled in soft gel capsules for ease of oral administration. Despite the
benefits, the liquid formulations are associated with various limitations, including dose uni-
formity, low stability, and interaction of the liquid formulation with the capsule shell may
lead to softening/brittleness of shell or change in taste perception or leakage of liquid from
the filled capsule [8]. These limitations have restricted the industrial product development
of liquid SNEDDS and have given a combusting interest to transform these liquid SNEDDS
formulations into a solid self-nanoemulsifying dosage form. The various attempts explored
to develop solid SNEDDS formulations include adsorption of liquids on solid carriers [9],
spray drying and spray cooling [10,11], and extrusion/spheronization for pellet design [12].
However, these approaches are also associated with product development issues such
as dose dilution [13], hindered flowability of powder formulation [14], incomplete drug
release due to adsorption of liquid onto silicates [13], and tolerability/toxicity issues [15].
In recent years, 3D printing has been widely explored to overcome various pharmaceu-
tical manufacturing issues and drug delivery challenges. The current research explores
the use of 3D printing for nanomedicine-based oral formulation development of poorly
soluble drugs.
3D printing is an additive manufacturing technique that enables layer-by-layer fabri-
cation of 3D structures in a customized dose and geometry driven digitally. The interest
in the field of 3D printing technology of pharmaceutical components has taken a big leap
with the approval of the first 3D printed tablet of levetiracetam (SPRITAM®) by US-FDA
in 2015 [16]. Recently in February 2021, the US FDA has given Investigational New Drug
(IND) approval to Triastek for its first 3D printed drug product (T19), which is used to
treat rheumatoid arthritis developed by using the 3D printing-based Melt Extrusion De-
position (MED) technique [17]. This IND approval by US-FDA is a further breakthrough
towards the success and advancement of 3D printing techniques in recent years for the
development of pharmaceutical products. In addition, 3D printing has been explored very
recently for the formulation of SNEDDS-based lidocaine suppositories for personalized
drug delivery utilizing pressure-assisted microsyringe (PAM)/extrusion-based 3D printing
technique [18]. The printed suppositories composed of Geloil™ SC, Gelucire® 48/16, and
Kolliphor® RH40 in varying composition exhibited delayed release of lidocaine and acted
as a patient-tailored formulation system. In another investigation, Vithani et al. developed
a solid lipid-based self-microemusifying drug delivery system for poorly soluble drugs
(such as fenofibrate and cinnarizine) [19]. This study demonstrated a proof-of-concept that
a 3D printing technique can be utilized to develop solid self-emulsifying drug delivery
systems without using solid adsorbents to convert the liquid self-emulsifying formulation
system into patient-tailored oral solid dosage forms. Furthermore, a lipid-based tablet
formulation system was fabricated from emulsion gels employing the PAM-based 3D
printing technique [20]. The study demonstrated the fabrication of an oil-in-water (O/W)
emulsion gel for a poorly water-soluble drug (Fenofibrate) incorporated with methylcel-
lulose, croscarmellose sodium as printable ink for the 3D printing process. The designed
3D printed tablets exhibited a rapid in vitro dispersion and digestion profile. Thus this
concept provides a piece of evidence to transform a lipid-based formulation system into a
solid dosage form utilizing 3D printing technique.
This work expands the use of semisolid extrusion-based 3D printing technique to
develop self-nanoemulsifying tablets of a poorly water-soluble drug where Dapagliflozin
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propanediol monohydrate (DAP) was selected as a model drug. It is a novel sodium-
glucose co-transporter-2 inhibitor (as an oral hypoglycemic agent), which is used in the
management of type II diabetes and acts by preventing the reabsorption of glucose in
kidneys [21]. The poor aqueous solubility and low permeability profile of DAP rationalize
its formulation design as solid-SNEDDS to improve the solubilization attributes and
dissolution profile exploring 3D printing technique for self-nanoemulsifying tablet design.
2. Materials and Method
2.1. Materials
Dapagliflozin propanediol monohydrate was provided by Jamjoom Pharmaceuticals,
Jeddah, Saudi Arabia. Capryol 90, Poloxamer 188, Polyethylene glycol (PEG) 6000, PEG
4000, Cremophore EL, and PEG 400 were purchased from Sigma Aldrich (Gillingham, UK).
Methanol was purchased from UFC Biotech (Riyadh, Saudi Arabia).
2.2. Choice of Material
Different formulation components (liquid and solid phase) were selected to design a
solid self-nanoemulsifying drug delivery system exploiting 3D printing technology. The
developed system consists of liquid phase containing oils and co-surfactant and solid phase
containing surfactant and solid matrix. The liquid phase was chosen based on the drug
solubility of DAP while the solid phase should have the ability to self-emulsify the liquid
phase into nanoemulsion as well as accommodate this liquid phase in their solid matrix.
2.3. Preparation and Optimization of Semisolid Extrudable Paste for 3D Printing of
Solid-SNEDDS
A semisolid paste of the selected liquid and solid phase for 3D printing was prepared
by the fusion method. The excipients consist of solid-phase were taken in a beaker and
melted at a temperature near 50 ◦C. After that, liquid phase excipients containing the
drug were added to this melted phase and mixed continuously with a magnetic stirrer to
form a clear homogeneous mass in a form of extrudable paste for the extrusion-based 3D
printing (pressure-assisted microsyringe−PAM) technique. This homogenous semi-solid
paste is then transferred to the extruder syringe and left to solidify at room temperature
for 30 min. To initialize the printing process, the temperature of the extruder syringe was
set to 45 ◦C for 10 min to attain thermal equilibrium wherein the solid mass inside the
extruder syringe gets ready as an extrudable paste for 3D printing. The consistency of
the paste was optimized for extrudability behavior and different process parameters (like
nozzle size, printing speed, printing pressure, and printing temperature) for 3D printing of
solid-SNEDDS.
2.4. 3D Printing of Solid-SNEDDS as a Tablet
The geometry of the 3D printed self-nanoemulsifying tablet was designed by Autodesk
CAD (Computer-Aided Design) software. The design was exported as an STL (Standard
Triangle Language) file and sliced through repetier software to form a printer readable
G-code. The solid-SNEDDS was designed in a form of self-nanoemulsifying circular tablets
of different diameters (8 mm, 10 mm, and 12 mm) utilizing a 3D printer (Biobot 1) based
on the PAM technique.
2.5. Characterization of the 3D Printed Self-Nanoemulsifying Tablet
The 3D printed self-nanoemulsifying tablet was characterized for the following
parameters:
2.5.1. Determination of Size and Weight
The size of the 3D printed self-nanoemulsifying tablets was measured using a digital
vernier caliper. The weight of individual 3D printed self-nanoemulsifying tablets was
measured to determine any weight variability. The weight variation of the 3D printed
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self-nanoemulsifying tablets was determined according to the European Pharmacopeia
(2.9.5) monograph [22].
2.5.2. Solid State Characterization
Attenuated Total Reflection-Fourier Transforms Infrared Spectroscopy (ATR-FTIR)
ATR-FTIR was performed to detect the drug-excipients interaction during the formu-
lation of self-nanoemulsifying tablets exploiting the 3D printing technique. The ATR-FTIR
spectra were obtained for the pure drug, placebo, and drug-loaded self-nanoemulsifying
tablets using an ATR-FTIR spectrometer (Agilent Cary 630 FTIR, Agilent Technologies, Dan-
bury, CT, USA). A small amount (10 mg) of the sample was taken and analyzed between
400–4000 cm−1 to assess the chances of any interactions between drug and formulation
excipients [23].
Powder X-ray Diffractometry (XRD)
The crystalline behavior of pure drug and physical state of DAP inside developed self-
nanoemulsifying tablets were determined by powder X-ray diffractometer (PW 3040/60,
PANalytical, Almelo, Netherlands) and patterns were recorded at 2θ in range of 3–100◦
with scanning speed 0.5◦/min at room temperature [23].
Differential Scanning Calorimetry (DSC)
Thermal behavior of pure drug, placebo, and drug-loaded self-nanoemulsifying tablets
were performed using Differential Scanning Calorimeter (TA DSC 25, TA Instruments,
New Castle, DE, USA). An accurately weighed amount of sample (5 mg) was placed in
a Tzero aluminum pan and sealed in a nitrogen environment. The nitrogen flow rate
was maintained at 50 mL/min with a heating rate of 10 ◦C/min utilizing an empty Tzero
aluminum pan as a reference [23].
2.5.3. Surface Morphology by Scanning Electron Microscopy (SEM)
The solid-state surface characterization of pure drug, placebo, and drug-loaded self-
nanoemulsifying tablets were determined by high-resolution field emission scanning
electron microscopy (JSM-7600F, JEOL, Tokyo, Japan) operated at an accelerating voltage
range of 2.0 to 5.0 kV. The sample powder was placed with the help of double-sided
adhesive glue provided with conductive gold coating. The elemental compositions of the
developed formulation as a drug-loaded delivery system were further confirmed by the
energy-dispersive X-ray spectroscopy (EDS) [24].
2.5.4. Determination of Droplet Size, Polydispersity Index (PdI), and Zeta Potential (ξ)
The 3D printed drug-loaded self-nanoemulsifying tablet was dispersed in distilled
water and characterized to determine the droplet size, polydispersity index (PdI), and
zeta potential (ξ) by dynamic light scattering technique using Zetasizer (Malvern Instru-
ments Ltd., Malvern, UK) at room temperature. The measurements were carried out in
triplicate. [25]
2.5.5. Determination of Percentage of Drug Content
The percentage of drug content (% drug) of 3D printed self-nanoemulsifying tablets
of each size was determined by dissolving the 3D printed tablets in methanol followed
by further dilutions to analyze through a UV spectrophotometer at λmax of 224 nm. The
percentage of drug content of each tablet size was determined. The drug content uniformity
was assessed according to the European Pharmacopeia (2.9.6) monograph to know the
uniformity of content in the customized dose of tablet printed through PAM-based 3D
printing technique [26].
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2.6. In Vitro Dissolution Study
The in vitro dissolution study was performed for 3D printed drug-loaded
self-nanoemulsifying tablets of each size using USP dissolution apparatus (type II). The
tablets were placed in 900 mL of the simulated gastric fluid (0.1 N HCl) as dissolution
media at pH 1.2. The dissolution study was performed at a temperature of 37 ± 0.5 ◦C and
stirring speed at 50 rpm under sink conditions. The 5 mL of aliquots were withdrawn at a
regular interval of 1, 3, 5, 10, 15, 20, 25, 30, 45, and 60 min. The samples were filtered and
analyzed through UV spectrophotometry at λmax of 224 nm. The drug release kinetics of
3D printed self-nanoemulsifying tablets were determined through the best-fit model [27].
3. Results and Discussion
3.1. Choice of Materials
The formulation components were selected to develop solid-SNEDDS as a self-
nanoemulsifying tablet. The developed formulation was composed of liquid phase consist
of oil system and co-surfactant while excipients of solid-phase serve both the purpose of
solidifying and emulsifying agent.
3.1.1. Selection of Liquid Phase
The liquid phase was selected based on the solubilizing capacity of DAP in different
oil systems. Among the tested oil systems like oleic acid, olive oil and peanut oil exhibited
less solubility of DAP (≤5 mg/mL) whereas capryol 90 and octanoic acid exhibited better
solubility of DAP 15.5 ± 1.24 mg/mL and 15.8 ± 1.06 mg/mL, respectively. The sponta-
neous nanoemulsion formation of a SNEDDS is facilitated by the addition of a co-surfactant
to the system, which helps to minimize the interfacial tension between the aqueous and
oily phases [28,29]. PEG 400 has been incorporated as a co-surfactant in the liquid phase as
it also exhibited desirable solubility of DAP (22.45 ± 1.12 mg/mL) to further improve the
drug loading. A combination of capryol 90, octanoic acid, and PEG 400 has been selected
in a ratio of 2:2:1 as a liquid phase system for the development of solid-SNEDDS as a
self-nanoemulsifying tablet exploiting 3D printing.
3.1.2. Selection of Solid Phase
The solid phase was selected based on its ability to self-nanoemulsify the chosen
liquid phase system along with the capability to accommodate the liquid phase system in
their crystal lattice. The mixture of poloxamer 188 along with PEG 6000 in a ratio of 1:1
was selected as the choice of surfactant and solidifying matrix for the chosen liquid phase.
It exhibited self-dispersibility and has the ability to self-nanoemulsify the chosen liquid
system into nanoemulsion in contact with the aqueous phase. Poloxamer 188, due to its
surface-active properties, has also been employed as a solubility enhancing solid dispersion
carrier for poorly water-soluble drugs [30]. The hydrophilicity and hydrophile-lipophile
balance (HLB) value of poloxamer 188 (HLB value = 29) make it a suitable candidate to form
an O/W nanoemulsion system [31]. Also, the addition of PEG 6000 along with poloxamer
188 as a solid matrix system for chosen liquid phase is helpful to reduce the overall absolute
amount of poloxamer 188 being a solidifying agent [32]. Therefore, a combination of
poloxamer 188 along with PEG 6000 in the ratio of 1:1 has been optimized as a solid
phase system to develop solid-SNEDDS as a self-nanoemulsifying tablet exploiting 3D
printing technology.
3.2. Preparation and Optimization of Semisolid Extrudable Paste for 3D Printing of
Solid-SNEDDS
3.2.1. Preparation of the Paste
A semisolid extrudable paste of the optimized composition of liquid and solid phase
in the ratio of 1:1.5 was prepared by fusion method with continuous stirring near to 50 ◦C.
The percentage composition of solid-SNEDDS as the self-nanoemulsifying tablet is shown
in Table 1.
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Table 1. Composition of 3D printed solid-SNEDDS as the self-nanoemulsifying tablet.








The influence of mixing of liquid and solid phase of SNEDDS composition through
fusion method with and without continuous stirring was observed and illustrated in Figure 1.
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Figure 1. Illustration depicting the effect of mixing on extrudable paste optimized for the 3D printing of self-nanoemulsifying
tablet through the PAM-based technique (a) Self-nanoemulsifying tablet (appearance of the surface is rough and granular)
printed through the mixing of liquid and solid phase by fusion method without continuous stirring. (b) Self-nanoemulsifying
tablet (appearance of the surface is smooth and uniform) printed through the mixing of liquid and solid phase by fusion
method with continuous stirring.
It was observed that the paste prepared without continuous mixing through magnetic
stirrer caused the appearance of the rough, granular surface of the self-nanoemulsifying
tablet upon 3D printing through PAM-based technique (Figure 1a). The appearance of the
uneven surface of the 3D printed self-nanoemulsifying tablet occurred upon loading of the
melted solution of the solid and liquid phase excipients without mixing in the extruder
syringe and allowing it to solidify in the extruder syringe before 3D printing of the tablets.
To overcome this issue, continuous mixing of the melted solution of the solid and
liquid phase excipients through a magnetic stirrer was carried out before loading in the
extruder syringe. The melted mass of the excipients of the solid phase was uniformly mixed
with the excipients of the liquid phase and the resultant liquid solution getting thicker as
semisolid paste under the influence of continuous magnetic stirring at room temperature
for 15 min. This paste of semisolid consistency was transferred into the extruder syringe
and subjected to 3D printing under similar conditions of room temperature and process
parameters. The continuous mixing of the formulation paste before filling in the extruder
syringe enabled the fabrication of smooth-surfaced 3D printed tablets (Figure 1b). This
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investigation validates the significance of mixing for the formation of extrudable paste of
semisolid consistency on the surface appearance of 3D printed self-nanoemulsifying tablets.
3.2.2. Optimization of Printing Process Parameters and Design of Printed Geometry
The prepared semisolid paste was extruded through the 3D printer to optimize the
process parameters and extrudability behavior. The semisolid paste was loaded into a
heated extruder syringe to initiate the extrusion process for 3D printing. The printing
was carried out at a temperature range starting from 30 to 50 ◦C. 3D printing at low
temperatures starting from 30 to 40 ◦C resulted in hindered extrusion. This temperature
range was observed to be not sufficient to extrude the loaded paste in the extruder syringe
under applied pressure conditions due to a lack of consistency. At high temperatures
(above 45–50 ◦C), the extrusion of paste was dripping with rapid flow due to liquefaction
of the loaded paste with the rise of temperature. It was observed that extrusion of loaded
paste showed better extrudability behavior under the influence of applied printing pressure
at a temperature range between 40 to 45 ◦C.
The printing was carried out at varying printing pressures starting from 40–80 PSI
upon thermal equilibrium (40 to 45 ◦C) of loaded paste for 10 min to optimize the printing
pressure, which influences the material extrusion rate. Printing at low pressure exhibited
slow extrusion material while printing at high pressure resulted in rapid extrusion of
the loaded material [33]. Finally, based on the extrusion behavior and uniformity in the
formation of printed layers, applied pressure of 60 PSI was found to be optimal for the 3D
printing of solid-SNEDDS.
The process parameters for 3D printing of solid-SNEDDS were further optimized for
the desirable nozzle diameter and printing speed. The nozzle diameter was optimized
depending on the consistency and extrudability behavior of the loaded paste in the extruder
syringe. Small diameter nozzles exhibited hindered extrusion due to the blockage of nozzle
upon solidification of extruding material in the nozzle tip, whereas larger diameter nozzles
resulted in increased thickness of the printed layer ultimately lowering the resolution
of the 3D printed structures [34]. Therefore, based on printed line assessment, a nozzle
diameter of 0.84 mm was optimal for 3D printing of the solid-SNEDDS at the previously
optimized pressure and temperature conditions. Furthermore, layer printing tests were
performed to optimize the printing speed of the motion of the print-head. Different
extrusion behaviors were observed upon varying the printing speed (6–16 mm/s). At low
speed, it resulted in over extrusion wherein very thick lines were formed with respect to
nozzle size. The printed lines were found bloated in appearance and no structural fineness
could be achieved with print speeds below 10 mm/s. At high speeds above 10 mm/s
under extrusion was observed, which appeared as broken lines due to the nozzle moving
faster than the extruded material. The printed lines thickness was also observed to be
smaller than the nozzle size. Based on the observations from the layer printing tests carried
out at varying speeds, a printing speed of 10 mm/s was optimized for the 3D printing of
solid-SNEDDS. Printing at an optimal speed was helpful to achieve the desired extrusion
rate and the thickness of the printed line was observed to be slightly more than the nozzle
size. It facilitates the adhesion of the printed layers and provides a desired geometrical
feature of the printed object [35]. Finally, based on the results obtained from the layer
printing test (shown in Supplementary Table S1), the printed layer/line dimensions were
measured (layer thickness and height), which paves the way to design the geometry of the
3D printed self-nanoemulsifying tablets.
3.3. 3D Printing of Solid-SNEDDS as the Self-Nanoemulsifying Tablet
3D printing of the designed geometry of self-nanoemulsifying tablets was carried out
as per the pre-optimized printing conditions. The optimized conditions of the process
parameters for 3D printing of the self-nanoemulsifying tablets are shown in Table 2.
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3.4. Characterization of the 3D Printed Self-Nanoemulsifying Tablet
3.4.1. Determination of Size, Weight Variation, and % Drug Content
The 3D printed tablets were evaluated for size, weight variation, and % drug content.
Table 3 shows the results of the three different sizes (A, B, and C) in terms of size (diameter
and height) as 8 mm × 3 mm, 10 mm × 3 mm, and 12 mm × 3 mm, respectively. The
average weights of tablets A, B, and C were found to be 193.36 ± 4.2 mg, 277.96 ± 3.6 mg,
and 439.76 ± 6.2 mg respectively. The average drug contents of tablets A, B, and C were
found to be 3.09 ± 0.05 mg, 5.00 ± 0.07 mg, and 7.03 ± 0.09 mg, respectively. The results
of the weight variation test for all three sizes were found to be within the pharmacopeial
limits (±7.5% for 12 mm size tablets and ±5% for 10 mm and 8 mm size tablets) [22,26]. It
was observed that the %drug content for all three sizes 3D printed self-nanoemulsifying
tablets of DAP were found to be within the pharmacopeial limit (99.46 ± 0.47, 99.12 ± 0.24,
and 99.4 ± 0.09 for tablet size of 8 mm, 10 mm, and 12 mm, respectively).





(Length × Height) in mm
Average Weight
(mg) % Drug Content
Tablet A (8 mm × 3 mm) (8.108 ± 0.152) × (3.116 ± 0.103) 193.36 ± 4.2 99.46 ± 0.47
Tablet B (10 mm × 3 mm) (10.052 ± 0.046) × (3.083 ± 0.100) 277.96 ± 3.6 99.12 ± 0.24
Tablet C (12 mm × 3 mm) (11.983 ± 0.275) × (3.039 ± 0.075) 439.76 ± 6.2 99.4 ± 0.09
3.4.2. Solid State Characterization
Attenuated Total Reflection-Fourier Transforms Infrared Spectroscopy (ATR-FTIR)
The FTIR spectra of DAP, placebo, and drug-loaded 3D printed self-nanoemulsifying
tablets were analyzed to observe the possibility of any interaction between the drug-
excipients (Figure 3). The FTIR spectra of DAP exhibited characteristic absorption peaks at
3350.14 cm−1, 2860.11cm−1, 1611.08 cm−1, and 1243.30 cm−1 due to hydroxyl OH bond
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stretching, C–H bond stretching, aromatic C=C bond stretching, and ester C–O bond
stretching, respectively. Moreover, the FTIR spectra of placebo 3D self-nanoemulsifying
tablet exhibited absorption peaks at 2878.04 cm−1 and 1279.07 cm−1 representing C–H
stretching and C–O stretching, respectively. The FTIR spectra of the 3D printed self-
nanoemulsifying tablet of DAP exhibited all the functional group peaks represented in
spectra of pure drug and placebo 3D printed self-nanoemulsifying tablet with no additional
peaks. This indicates that there was no interaction between the drug and excipients utilized
in the preparation of the 3D printed self-nanoemulsifying tablets [23].




Figure 3. FT-IR spectra of (a) DAP; (b) placebo self-nanoemulsifying tablet; (c) self-nanoemulsifying tablet of DAP. Fig re 3. F -I s ectra of (a) ; ( ) lacebo self-nanoe lsifying tablet; (c) self-nanoe lsifying tablet of .
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Differential Scanning Calorimetry (DSC)
The DSC thermogram of DAP, placebo, and drug-loaded 3D printed
self-nanoemulsifying tablets were analyzed and shown in Figure 4. It is observed that DAP
exhibited a sharp endothermic peak at 80.6 ◦C, indicating the melting point of the drug and
its crystalline nature. No distinct peaks were observed for the physical mixture of excipi-
ents (poloxamer 188 and PEG 6000) near this range of temperature. A sharp endothermic
peak near 52 ◦C was observed that correlates to the melting points of the physical mixture
of poloxamer 188 and PEG 6000. The DSC thermogram of the drug-loaded tablets did
not show the characteristic endothermic peak of DAP. This indicates that DAP remains in
the solubilized state in liquid phase components of the 3D printed self-nanoemulsifying
tablets and is molecularly dispersed in the crystal lattice of the solid phase components
(poloxamer 188 and PEG 6000) [36].




Figure 4. DSC thermogram of (a) DAP; (b) physical mixture of poloxamer 188 and PEG 6000; (c) self-nanoemulsifying 
tablet of DAP. 
Figure 4. DSC thermogram of (a) DAP; (b) physical mixture of poloxamer 188 and PEG 6000;
(c) self-nanoemulsifying tablet of DAP.
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Powder X-ray Diffractometry (XRD)
The molecular dispersion state of the drug in the developed formulation system was
further validated by powder-XRD analysis. The X-ray diffractograms of DAP, placebo, and
drug-loaded 3D printed self-nanoemulsifying tablets were analyzed and shown in Figure 5.
The typical diffraction patterns of DAP revealed a highly crystalline structure. Moreover,
these typical diffraction patterns of DAP were lacking in the drug-loaded 3D printed self-
nanoemulsifying tablet. This indicates that the encapsulated drug molecules remain in the
solubilized state in liquid phase components of the 3D printed self-nanoemulsifying tablet
and molecularly dispersed in the crystal lattice of the solid phase components (poloxamer
188 and PEG 6000) [23,36].




Figure 5. X-ray diffraction pattern of (a) DAP; (b) placebo self-nanoemulsifying tablet; (c) self-
nanoemulsifying tablet of DAP. 
3.4.3. Surface Morphology by Scanning Electron Microscopy (SEM) 
The surface morphology of the pure drug sample and 3D printed self-nanoemulsify-
ing systems as placebo and drug-loaded tablets were determined through SEM analysis 
(Figure 6). The SEM image pure drug sample (Figure 6a) differs in appearance compared 
to the SEM image of the 3D printed self-nanoemulsifying tablet (Figure 6b,c). Moreover, 
the SEM image of the 3D printed self-nanoemulsifying tablet (Figure 6b) reveals that 
poloxamer 188 and PEG 6000 act as a suitable solid carrier system to accommodate the 
liquid phase SNEDDS into its crystal lattice through complete solidification of a mixture 
of liquid and solid phase components of the printed tablet. Furthermore, the SEM image 
of the drug-loaded self-nanoemulsifying tablet (Figure 6c) revealed that DAP is com-
pletely encapsulated in the solid matrix of poloxamer 188 and PEG 6000. The surface 
Figure 5. X-ray diffraction pattern of (a) DAP; (b) placebo self-nanoemulsifying tablet; (c) self-
nanoemulsifying tablet of DAP.
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3.4.3. Surface Morphology by Scanning Electron Microscopy (SEM)
The surface morphology of the pure drug sample and 3D printed self-nanoemulsifying
systems as placebo and drug-loaded tablets were determined through SEM analysis
(Figure 6). The SEM image pure drug sample (Figure 6a) differs in appearance compared
to the SEM image of the 3D printed self-nanoemulsifying tablet (Figure 6b,c). Moreover,
the SEM image of the 3D printed self-nanoemulsifying tablet (Figure 6b) reveals that
poloxamer 188 and PEG 6000 act as a suitable solid carrier system to accommodate the
liquid phase SNEDDS into its crystal lattice through complete solidification of a mixture of
liquid and solid phase components of the printed tablet. Furthermore, the SEM image of
the drug-loaded self-nanoemulsifying tablet (Figure 6c) revealed that DAP is completely
encapsulated in the solid matrix of poloxamer 188 and PEG 6000. The surface morphology
of the DAP (Figure 6a) as inspected in SEM image analysis reveals the mosaic-like grains
of varying sizes within microranges. Well-defined grain boundaries are explicitly visible in
the image for almost all the grains, indicating the grain-like structure of DAP. An SEM im-
age of the placebo (Figure 6b) and drug-loaded tablet (Figure 6c) shows the agglomerated
structure of the material. Compared to the placebo tablet ((Figure 6b), the morphology of
the drug-loaded tablet (Figure 6c) is almost similar and shows the agglomerated growth
of the material. More accurately, the morphology of the drug-loaded tablet represents the
dominating surface morphology of the placebo tablet. It indicates that the DAP has been
dispersed/distributed into the lattices of placebo tablet.
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The elemental composition of 3D printed self-nanoemulsifying tablet formulation as a
drug-loaded delivery system was further confirmed by EDS analysis (Figure 7c). It showed
the presence of characteristics peak for chlorine in the EDS spectrum of the 3D printed
self-nanoemulsifying tablet of DAP. Moreover, placebo 3D printed self-nanoemulsifying
tablets lack the presence of characteristics peak for chlorine in the EDS spectrum (Figure 7b).
This reveals that the developed formulation successfully accommodates the solubilized
form of DAP in the crystal lattice of the printed tablet.




Figure 7. EDS analysis (a) spectrum of Dapagliflozin propanediol monohydrate [C21H25ClO6] showing the presence of 
carbon [C], oxygen [O] and chlorine [Cl] as characteristic peak for its elemental composition (b) spectrum of placebo 3D 
printed self-nanoemulsifying tablet showing the presence of carbon [C], and oxygen [O] as characteristic peak for its ele-
mental composition (c) spectrum of drug-loaded 3D printed self-nanoemulsifying tablet showing the presence of carbon 
[C], oxygen [O] and chlorine [Cl] as characteristic peak for its elemental composition. 
3.4.4. Determination of Droplet Size, Polydispersibility Index (PdI), and Zeta Potential 
(ξ) 
The droplet size distribution, PdI, and zeta potential of 3D printed self-nanoemulsi-
fying tablets of DAP were determined by dynamic light scattering technique through zeta 
sizer. The average droplet size of the 3D printed self-nanoemulsifying tablets of DAP was 
found to be 104.7 ± 3.36 nm with a PdI value of 0.063 ± 0.024 (Figure 8a). This droplet size 
range of around 100 nm would improve the drug dissolution and absorption upon oral 
administration because smaller droplets of drug-loaded carrier systems have a greater 
surface area available to enhance drug absorption and systemic bioavailability [37,38]. 
Furthermore, the stability of the drug-loaded nanoemulsion system is subjective to the 
surface charge. The higher surface charge will increase electrical repulsive forces, which 
prevent the nanodroplets coalescence in the gastrointestinal fluid [39]. The surface charge 
on nanoemulsion droplets generated from 3D printed self-nanoemulsifying tablets of 
DAP in the presence of aqueous phase was found to have a negative polarity with zeta 




Figure 7. EDS analysis (a) spectrum of Dapagliflozin propanediol monohydrate [C21 25 l 6] showing the presence of
carbon [C], oxygen [O] and chlorine [Cl] as characteristic peak for its elemental composition (b) spectrum of placebo
3D printed self-nanoemulsifying tablet showing the presence of carbon [C], and oxygen [O] as characteristic peak for its
elemental composition (c) spectrum of drug-loaded 3D printed self-nanoemulsifying tablet showing the presence of carbon
[C], oxygen [O] and chlorine [Cl] as characteristic peak for its elemental composition.
3.4.4. Determination of Droplet Size, Polydispersibility Index (PdI), and Zeta Potential (ξ)
The droplet size distribution, PdI, and zeta potential of 3D printed self-nanoemulsifying
tablets of DAP were determined by dynamic light scattering technique through zeta sizer.
The average droplet size of the 3D printed self-nanoemulsifying tablets of DAP was found
to be 104.7 ± 3.36 nm with a PdI value of 0.063 ± 0.024 (Figure 8a). This droplet size
range of around 100 nm would improve the drug dissolution and absorption upon oral
administration because smaller droplets of drug-loaded carrier systems have a greater
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surface area available to enhance drug absorption and systemic bioavailability [37,38].
Furthermore, the stability of the drug-loaded nanoemulsion system is subjective to the
surface charge. The higher surface charge will increase electrical repulsive forces, which
prevent the nanodroplets coalescence in the gastrointestinal fluid [39]. The surface charge
on nanoemulsion droplets generated from 3D printed self-nanoemulsifying tablets of DAP
in the presence of aqueous phase was found to have a negative polarity with zeta potential
−6.84 ± 0.34 mV (Figure 8b). This indicates that the generated nanoemulsion system on
self-nanoemulsification of 3D printed tablet inside the gastrointestinal tract acts as a stable
drug carrier system, which would be helpful in improving the absorption profile of the
encapsulated drug.
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3.5. In Vitro Dissolution Study and Drug Release Kinetics
The in vitro dissolution profile of the P-loaded 3 printed self-nanoe ulsifying
tablets revealed an i ediate-release drug profile for all three tablet sizes (8 , 10 ,
a 12 ) as s o i i re 9. e c lati e r release fro 3 ri te self-
lsif ing tablets ithin 25 in was 95.27 ± 0.21, 89.27 ± 0.15, and 9.87 ± 0.12
for the tablets of 8 mm, 10 mm, and 12 m diameter, respectiv ly. Th smaller tablets
(8 mm) exhibited a higher % cumulativ drug release comp ed to l rger di m er tablets
(10 mm or more). This is becau e of the faster release rate of th smaller size tablets
compared to larger ones due to the high surface a ea to volume ratio (SA:V) of sma ler
tablets. Tablets with hig SA:V exhibit a higher rate of release due to the high l vel of
interaction be ween the surfac of the tablets an the surr unding media [40]. For 3D
printed self-nano mulsifying tablets, th SA:V of 8 mm diameter tablet is 1.16:1.00 whereas
the SA:V of 10 m and 12 mm diameter tablets is 1. 6:1.00 and 1.00:1.00, respec ively. Ap-
proximately 95.0% of DAP was r leas d from all three sizes of tablets in 30 min. The use
of poloxamer 188 a an emulsifying an s lidifying agent did not hinder/delay the rate
of self-nanoemulsification of solid-SNEDDS as the drug-lipid phase remain unifor ly
dispersed in the microstructure of poloxamer 88 PEG 6000 [19], and resulted in th
formation of stable nanomedicine-based solid dosage forms utilizi g 3D printing technol-
ogy. The traditional solidification techniques utilized solid carrier as an adsorbent (such as
colloidal silica, dextran, microcrystalline cellulose, and lactose, etc.) and converted to solid
SNEDDS-based pellets through spray drying, spray cooling, and extrusion-spheronization
technique [41,42]. These techniques require the addition of a high amount of solid carrier
to adsorb the liquid SNEDDS for their conversion into solid-SNEDDS. The addition of a
higher amount of solid adsorbent hinders the self-nanoemulsification of SNEDDS and may
require incorporation of a higher amount of surfactant to facilitate self-nanoemulsification
and formation of colloidal dispersion upon contact with the aqueous phase [43,44]. More-
over, the addition of high amounts of adsorbent may also affect the dose uniformity,
reproducibility, and raise safety concern [45,46].
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10 mm, and 12 mm).
The drug release kinetics model describes a particular drug release characteristics from
the developed for ulation system, which exhibits the actual mass transport mechanism of
drug release involved to quantitatively predict the exact drug release kinetics. The drug re-
lease kinetics from 3D printed self-nanoemulsifying tablet formulation was best described
by the Higuchi model. This observation aligns with the previously published literature
report related to drug r lea e kinetic behavior for a solid-SNEDDS [47]. The developed
formulation system exhibited the best linearity and regression coefficient values of 0.986
with a release exponent (n) value of 0.191 for the tablet of 8 mm size whereas the regression
coefficient and n value for the tablet of 10 mm and 12 mm diameters were 0.980 with n
value of 0.265 and 0.985 wi n value of 0.221, respectively. This indi at s that the drug
release from the developed formulation system was a square root of time. Furthermore, n
values of release exponent of <0.5 indicate that the 3D printed self-nanoemulsifying tablet
of DAP exhibited fickian diffusion. It indicates an immediate-release drug profile from a
developed formulation system, without depicting any lag time [48]. Thus, the 3D printing
technology was successfully utilized to design and develop nanomedicine-based solid
dosage forms of DAP with immediate-release drug profiles. This investigation further ex-
tends the line of research carried out in the area of SNEDDS-based pharmaceutical product
development [18–20] utilizing the semisolid extru io -based 3D printing t chnique.
4. Conclusions
This work combines SNEDDS and 3D printing technology approach to enhance the
biopharmaceutical attributes of DAP and provide the ability to di pense tailor d doses
for diabetic patients. The use of poloxamer 188, which acts as a surfactant and solidifying
agent has led to the development of a solid self-nanoemulsifying tablet without using an
additional adsorbent or carrier system. The developed 3D printed self-nanoemulsifying
tablet in aqueous dispersion exhibited encapsulation of the drug in stable nanoemulsion
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system with negative surface charge. The fabricated 3D printed tablet showed no interac-
tion of drug with formulation excipients during the printing process and the existence of
the drug in a solubilized and molecularly dispersed state in the solid carrier system, which
is described through solid-state characterization. The 3D printed self-nanoemulsifying
tablet showed an immediate-release drug profile for all three tablet sizes (8 mm, 10 mm,
and 12 mm) with improved biopharmaceutical attributes. Thus, the 3D printing technique
provides an alternative to design and develop self-nanoemulsifying solid dosage forms for
poorly water-soluble drugs.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13070993/s1, Figure S1: Schematic illustration presenting the generation of drug
enclosed nanoemulsion system upon self-nanoemulsification of 3D printed self-nanoemulsifying
tablets in gastrointestinal fluid, Table S1: Optimization of extrudability behavior based on printed
layer/line dimension (thickness and height).
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